Bal Pharma Limited (NSE:BALPHARMA)

Bal Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	17.52	41.96	14.87	11.13	10.23
Short-Term Investments	-	86.59	157.33	59.76	47.3	29.48
Cash & Short-Term Investments	105.19	104.1	199.29	74.63	58.43	39.71
Cash Growth	-47.54%	-47.76%	167.05%	27.72%	47.14%	13.24%
Accounts Receivable	-	924.44	996.22	939.76	753.12	671.97
Other Receivables	-	31.07	32.81	27.56	51.87	42.99
Receivables	-	966.83	1,043	976.92	828.67	735.6
Inventory	-	1,030	878.11	980.05	743.96	603.85
Prepaid Expenses	-	13.44	9.69	7.2	5.86	0.8
Other Current Assets	-	234.13	211.66	242.77	208.79	261.51
Total Current Assets	-	2,349	2,342	2,282	1,846	1,641
Property, Plant & Equipment	-	737.76	647.89	621.79	571.85	575.09
Long-Term Investments	-	42.35	2.81	13.98	18.09	23.86
Goodwill	-	38.27	38.27	38.29	38.29	38.29
Other Intangible Assets	-	9.79	12.49	13.16	2.09	0.59
Long-Term Deferred Tax Assets	-	4.1	-	21.67	-	-
Long-Term Deferred Charges	-	110.18	101.32	91.41	77.83	71.89
Other Long-Term Assets	-	65.73	52.82	48.9	47.53	45.78
Total Assets	-	3,357	3,198	3,132	2,605	2,401
Accounts Payable	-	816.86	774.64	789.23	655.64	471.67
Accrued Expenses	-	73.14	37.77	34.69	70.82	58.64
Short-Term Debt	-	1,073	957.61	927.17	707.49	821.21
Current Portion of Long-Term Debt	-	116.7	74.88	77.6	58.79	52.72
Current Portion of Leases	-	6.38	12.77	8.55	7.62	3.08
Current Income Taxes Payable	-	-	22.18	60.06	43.93	6.14
Other Current Liabilities	-	108.83	150.72	196.06	112.17	111.88
Total Current Liabilities	-	2,195	2,031	2,093	1,656	1,525
Long-Term Debt	-	314	363.49	305.23	270.14	239.32
Long-Term Leases	-	12.9	13.74	12.25	22.54	16.15
Long-Term Deferred Tax Liabilities	-	-	15.49	28.69	6.04	26.32
Other Long-Term Liabilities	-	13.64	12.75	12.8	25.42	24.72
Total Liabilities	-	2,583	2,479	2,495	2,020	1,867
Common Stock	-	159.21	158.04	156.9	148.22	148.22
Additional Paid-In Capital	-	319.78	312.87	301.84	266.77	266.77
Retained Earnings	-	297.62	245.04	171.4	160.33	119.03
Comprehensive Income & Other	-	-2.45	4.09	7.75	10.95	1.79
Total Common Equity	774.16	774.16	720.04	637.89	586.27	535.82
Minority Interest	-	-0.12	-0.33	-0.87	-1.34	-2.28
Shareholders' Equity	774.04	774.04	719.72	637.02	584.92	533.54
Total Liabilities & Equity	-	3,357	3,198	3,132	2,605	2,401
Total Debt	1,521	1,523	1,423	1,331	1,067	1,132
Net Cash (Debt)	-1,416	-1,419	-1,223	-1,256	-1,008	-1,093
Net Cash Per Share	-90.60	-89.51	-77.73	-80.06	-68.02	-76.96
Filing Date Shares Outstanding	15.43	15.92	15.8	15.69	15.57	14.82
Total Common Shares Outstanding	15.43	15.92	15.8	15.69	14.82	14.82
Working Capital	-	153.72	311.04	188.22	189.26	116.15
Book Value Per Share	39.09	48.63	45.56	40.66	39.55	36.15
Tangible Book Value	615.92	726.1	669.28	586.45	545.89	496.94
Tangible Book Value Per Share	31.10	45.61	42.35	37.38	36.83	33.53
Land	-	172.71	148.93	148.93	79.1	79.1
Buildings	-	239.38	233.21	222.2	214.15	208.79
Machinery	-	763.63	671.8	613.08	558.05	539.09
Construction In Progress	-	27.86	4.72	-	16.12	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.